Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE - Delayed Quote USD

Pfizer Inc. (PFE)

Compare
25.21
+0.20
+(0.80%)
At close: March 28 at 4:00:02 PM EDT
25.13
-0.08
(-0.34%)
After hours: March 28 at 7:59:48 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Albert Bourla D.V.M., Ph.D. Chairman of the Board & CEO 9.82M 680k 1962
Mr. David M. Denton CFO & Executive VP 4.55M -- 1965
Dr. Chris Boshoff FMedSci, M.D., Ph.D. Chief Scientific Officer and President of Research & Development 4.71M 51.94k 1964
Ms. Jennifer B. Damico Senior VP, Controller & Principal Accounting Officer -- -- 1968
Ms. Lidia L. Fonseca Executive VP and Chief Digital & Technology Officer -- -- 1969
Ms. Francesca M. DeMartino Chief Investor Relations Officer -- -- --
Mr. Douglas M. Lankler Executive VP & Chief Legal Officer 1.76M -- 1966
Ms. Payal Sahni Becher Chief People Experience Officer & Executive VP -- -- 1975
Ms. Sally M. Susman Executive VP & Chief Corporate Affairs Officer -- -- 1962
Dr. Michael S. Vincent M.D., Ph.D. Senior VP and Chief Scientific Officer of Inflammation & Immunology -- -- --

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323 https://www.pfizer.com
Sector: 
Healthcare
Full Time Employees: 
81,000

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate Governance

Pfizer Inc.’s ISS Governance QualityScore as of March 1, 2025 is 5. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 29, 2025 at 12:30 PM UTC

Pfizer Inc. Earnings Date

Recent Events

March 13, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 7, 2025 at 12:00 AM UTC

Dividend Date

February 27, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 4, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 24, 2025 at 12:00 AM UTC

Ex-Dividend Date

December 18, 2024 at 3:00 PM UTC

Pfizer Pflash: A Spotlight On Clostridioides difficile (C. diff) Vaccine Development

December 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 4, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers